A 20-year overview of fertility preservation in boys: new insights gained through a comprehensive international survey
Top Cited Papers
Open Access
- 1 January 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2024 (2) , hoae010
Abstract
Twenty years after the inception of the first fertility preservation programme for pre-pubertal boys, what are the current international practices with regard to cryopreservation of immature testicular tissue? Worldwide, testicular tissue has been cryopreserved from over 3000 boys under the age of 18 years for a variety of malignant and non-malignant indications; there is variability in practices related to eligibility, clinical assessment, storage, and funding. For male patients receiving gonadotoxic treatment prior to puberty, testicular tissue cryopreservation may provide a method of fertility preservation. While this technique remains experimental, an increasing number of centres worldwide are cryopreserving immature testicular tissue and are approaching clinical application of methods to use this stored tissue to restore fertility. As such, standards for quality assurance and clinical care in preserving immature testicular tissue should be established. A detailed survey was sent to 17 centres within the recently established ORCHID-NET consortium, which offer testicular tissue cryopreservation to patients under the age of 18 years. The study encompassed 60 questions and remained open from 1 July to 1 November 2022. Of the 17 invited centres, 16 completed the survey, with representation from Europe, Australia, and the USA. Collectively, these centres have cryopreserved testicular tissue from patients under the age of 18 years. Data are presented using descriptive analysis. Since the establishment of the first formal fertility preservation programme for pre-pubertal males in 2002, these 16 centres have cryopreserved tissue from 3118 patients under the age of 18 years, with both malignant (60.4%) and non-malignant (39.6%) diagnoses. All centres perform unilateral biopsies, while 6/16 sometimes perform bilateral biopsies. When cryopreserving tissue, 9/16 centres preserve fragments sized ≤5 mm3 with the remainder preserving fragments sized 6–20 mm3. Dimethylsulphoxide is commonly used as a cryoprotectant, with medium supplements varying across centres. There are variations in funding source, storage duration, and follow-up practice. Research, with consent, is conducted on stored tissue in 13/16 centres. While this is a multi-national study, it will not encompass every centre worldwide that is cryopreserving testicular tissue from males under 18 years of age. As such, it is likely that the actual number of patients is even higher than we report. Whilst the study is likely to reflect global practice overall, it will not provide a complete picture of practices in every centre. Given the research advances, it is reasonable to suggest that cryopreserved immature testicular tissue will in the future be used clinically to restore fertility. The growing number of patients undergoing this procedure necessitates collaboration between centres to better harmonize clinical and research protocols evaluating tissue function and clinical outcomes in these patients. K.D. is supported by a CRUK grant (C157/A25193). R.T.M. is supported by an UK Research and Innovation (UKRI) Future Leaders Fellowship (MR/S017151/1). The MRC Centre for Reproductive Health at the University of Edinburgh is supported by MRC (MR/N022556/1). C.L.M. is funded by Kika86 and ZonMW TAS 116003002. A.M.M.v.P. is supported by ZonMW TAS 116003002. E.G. was supported by the Research Program of the Research Foundation—Flanders (G.0109.18N), Kom op tegen Kanker, the Strategic Research Program (VUB_SRP89), and the Scientific Fund Willy Gepts. J.-B.S. is supported by the Swedish Childhood Cancer Foundation (TJ2020-0026). The work of NORDFERTIL is supported by the Swedish Childhood Cancer Foundation (PR2019-0123; PR2022-0115), the Swedish Research Council (2018-03094; 2021-02107), and the Birgitta and Carl-Axel Rydbeck’s Research Grant for Paediatric Research (2020-00348; 2021-00073; 2022-00317; 2023-00353). C.E is supported by the Health Department of the Basque Government (Grants 2019111068 and 2022111067) and Inocente Inocente Foundation (FII22/001). M.P.R. is funded by a Medical Research Council Centre for Reproductive Health Grant No: MR/N022556/1. A.F. and N.R. received support from a French national research grant PHRC No. 2008/071/HP obtained by the French Institute of Cancer and the French Healthcare Organization. K.E.O. is funded by the University of Pittsburgh Medical Center and the US National Institutes of Health HD100197. V.B-L is supported by the French National Institute of Cancer (Grant Seq21-026). Y.J. is supported by the Royal Children’s Hospital Foundation and a Medical Research Future Fund MRFAR000308. E.G., N.N., S.S., C.L.M., A.M.M.v.P., C.E., R.T.M., K.D., M.P.R. are members of COST Action CA20119 (ANDRONET) supported by COST (European Cooperation in Science and Technology). The Danish Child Cancer Foundation is also thanked for financial support (C.Y.A.). The authors declare no competing interests. N/A.Keywords
Funding Information
- CRUK (C157/A25193)
- UK Research and Innovation
- MRC Centre for Reproductive Health
- MRC (MR/N022556/1)
- Kika86
- ZonMw
- Research Program of the Research Foundation—Flanders (G.0109.18N)
- Swedish Childhood Cancer Foundation (TJ2020-0026)
- Swedish Childhood Cancer Foundation (PR2019-0123, PR2022-0115)
- Swedish Research Council (2018-03094, 2021-02107)
- Birgitta and Carl-Axel Rydbeck’s Research Grant for Paediatric Research (2020-00348, 2021-00073, 2022-00317, 2023-00353)
- Health Department of the Basque Government (2019111068, 2022111067)
- Inocente Inocente Foundation (FII22/001)
- Medical Research Council
- University of Pittsburgh Medical Center
- US National Institutes of Health (HD100197)
- French National Institute of Cancer (Seq21-026)
- Royal Children’s Hospital Foundation
- Medical Research Future Fund (MRFAR000308)
- The Danish Child Cancer Foundation
This publication has 47 references indexed in Scilit:
- Spermatogonial Stem Cell Transplantation into Rhesus Testes Regenerates Spermatogenesis Producing Functional SpermCell Stem Cell, 2012
- Options for fertility preservation in prepubertal boysHuman Reproduction Update, 2010
- Propagation of Human Spermatogonial Stem Cells In VitroJAMA, 2009
- Methods of cryopreservation of testicular tissue with viable spermatogonia in pre-pubertal boys undergoing gonadotoxic cancer treatmentHuman Reproduction, 2007
- Spermatogonial survival after grafting human testicular tissue to immunodeficient miceHuman Reproduction, 2005
- Limited survival of adult human testicular tissue as ectopic xenograftHuman Reproduction, 2005
- Cryopreservation of intact testicular tissue from boys with cryptorchidismHuman Reproduction, 2005
- Optimizing cryopreservation of human testicular tissue: comparison of protocols with glycerol, propanediol and dimethylsulphoxide as cryoprotectantsHuman Reproduction, 2005
- Cryopreservation of Sperm From Adolescents and Adults With MalignanciesJournal of Andrology, 2004
- Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyteThe Lancet, 1992